Welcome to our dedicated page for ONCOTELIC THERAPEUTCS news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on ONCOTELIC THERAPEUTCS stock.
ONCOTELIC THERAPEUTCS INC (OTLC) is a biotechnology company focused on developing innovative therapies for cancer treatment. With a strong emphasis on research and development, the company is committed to bringing novel treatment options to patients in need. Leveraging cutting-edge technologies and strategic partnerships, ONCOTELIC THERAPEUTCS aims to revolutionize cancer care and improve patient outcomes. The company's pipeline includes promising drug candidates targeting various types of cancer, with a focus on precision medicine and personalized treatment approaches. Dedicated to advancing the field of oncology, ONCOTELIC THERAPEUTCS is at the forefront of the fight against cancer.
Oncotelic Therapeutics (OTCQB:OTLC) has announced the implementation of its AI platform PDAOAI, designed for document search and analysis in knowledge-based industries. The platform, accessible via PDAO tokens, uses advanced semantic filtering and LLM-based contextual answering to enable precise queries across large document sets.
The system has already demonstrated success at Sapu Bioscience, a subsidiary of GMP Biotechnology (where Oncotelic holds 45% ownership), helping achieve GMP compliance within one year through efficient staff training and SOP implementation. The platform will be governed through Pet2DAO using PDAO tokens, ensuring transparent, community-driven governance.
Oncotelic Therapeutics (OTCQB:OTLC) announced its upcoming presentations at SITC 2024, led by Dr. Cynthia Lee, VP of R&D. The company will present three abstracts focusing on TGFB2 therapeutics and cancer research:
1. Abstract 198: Examining TGFB2 mRNA levels' interaction with various markers in PDAC survival
2. Abstract 218: Studying prognostic impact of TGFB2 mRNA levels in low-grade gliomas
3. Abstract 1444: Meta-analysis comparing treatments for unresectable PDAC tumors
Dr. Lee, who leads the company's R&D programs and GMP facility in San Diego, will present the Sapu Bio pipeline of TGFB2 therapeutics.
Oncotelic Therapeutics (OTCQB:OTLC) has announced its fourth publication in its TGFB2 research series. Clinical data revealed significant survival improvements in pancreatic cancer patients with low expression levels of both TGFB2 and either IRF9 or IFI27, extending median overall survival from 16-20 months to 72 months. This validates the therapeutic potential of targeting IRF9 and IFI27 knockdown in TGFB2 therapeutics. The company has published four peer-reviewed articles focusing on TGFB2's role in various cancers, including pancreatic ductal adenocarcinoma, low-grade gliomas, and pediatric diffuse intrinsic pontine glioma.
Oncotelic Therapeutics (OTCQB:OTLC) announced its participation at the Precision in Drug Discovery & Preclinical Summit in San Diego. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented the company's Sapu Bio pipeline of TGFB2 therapeutics. Both scientists are focused on developing treatments for pancreatic and brain cancers through nanomedicine and precision drug development approaches.
Oncotelic Therapeutics (OTCQB:OTLC) announced that Product Manager Scott Myers will present at the 2nd Global Summit on Artificial Intelligence. The digital summit focuses on 'Pioneering the New Era: Advancing Global Development through Artificial Intelligence.' Myers will discuss the PubMed Corpus Builder, part of the Orion AI Suite developed by Sapu Bioscience
The PubMed Corpus Builder uses AI and LLMs to create comprehensive document corpora from the PubMed Central Database. It generates multiple search queries, downloads documents, and refines selection using vector search. The tool can identify documents with specific types of graphs and interpret them using multimodal technology. This system significantly accelerates the research process, allowing scientists to efficiently filter through hundreds of documents in minutes.
Oncotelic Therapeutics (OTCQB:OTLC) announced that its CEO, Dr. Vuong Trieu, will present at the 20th Annual Congress of International Drug Discovery Science & Technology in Budapest, Hungary, from June 17-19, 2024. Dr. Trieu will discuss OT-101, an antisense therapeutic targeting TGFB2, currently in phase 3 clinical trials for pancreatic cancer and glioblastoma. The presentation will also cover the potential of OT-101 in treating colorectal cancer (CRC), supported by clinical and bioinformatic analyses. Preliminary results indicate that OT-101 might prolong progression-free survival in CRC patients, particularly those with low TGFB2 and TGFM6 expression. Further analysis reveals a significant survival benefit in patients with low TGFB2/TGM6 expression. These findings could position OT-101 as a promising treatment for CRC, melanoma, and pancreatic cancer.
Oncotelic Therapeutics (OTCQB: OTLC) announced on May 30, 2024, that its CEO, Dr. Vuong Trieu, will attend the BIO International 2024 meeting in San Diego from June 3-6. The BIO International Convention is the largest biotech industry event, attracting over 18,500 global leaders.
Oncotelic Therapeutics announced that Chief Clinical Officer Dr. Anthony Maida will present at the ASCO 2024 meeting. Key topics include:
1. A meta-analysis (abstract e16318) comparing serious adverse events, overall survival, and progression-free survival in pancreatic adenocarcinoma patients treated with modified FOLFIRINOX versus the standard regimen.
2. A study (abstract e14564) on the prognostic impact of TGFB2 mRNA levels, interferon-gamma receptor activation of IRF5, and CD276/B7-H3 expression in low-grade gliomas.
The presentation aims to provide insights into treatment outcomes and prognostic factors in these cancers.
Oncotelic Therapeutics, Inc (OTCQB:OTLC) will be presenting at the Biopharma Nexus Conference in San Diego 2024. Dr. Andy Hu, Nanomedicine Manager, will discuss Nanomedicines: Past, Present, Future. Dr. Hu is an expert in nanomedicine and biotherapeutics, aiming to enhance human health through innovative technologies.
Oncotelic Therapeutics, Inc. has agreed to sell its necroptosis cancer therapy assets to Mosaic ImmunoEngineering, Inc. The deal includes rights to Oncotelic's clinical-stage necroptosis cancer therapies and AI technologies for identifying immunotherapy combinations. Mosaic will issue $15 million in CPMV shares to Oncotelic, with potential for an additional $15 million in shares. The Mosaic team, experienced in bringing oncology products to market, will lead the development. Both companies will collaborate for a smooth transition of technologies. The agreement is subject to negotiation of definitive agreements and customary conditions.
FAQ
What is the current stock price of ONCOTELIC THERAPEUTCS (OTLC)?
What is the market cap of ONCOTELIC THERAPEUTCS (OTLC)?
What is ONCOTELIC THERAPEUTCS INC (OTLC) focused on?
What sets ONCOTELIC THERAPEUTCS apart from other biotech companies?
What does the pipeline of ONCOTELIC THERAPEUTCS include?
How does ONCOTELIC THERAPEUTCS contribute to the field of oncology?
What is the mission of ONCOTELIC THERAPEUTCS?
Is ONCOTELIC THERAPEUTCS committed to patient-centric care?
What are some recent achievements of ONCOTELIC THERAPEUTCS?
How does ONCOTELIC THERAPEUTCS leverage cutting-edge technologies?
What partnerships does ONCOTELIC THERAPEUTCS have in the industry?
How does ONCOTELIC THERAPEUTCS aim to revolutionize cancer care?
